Anti-PD-L1 antibody [MIH6] - Low endotoxin, Azide free (ab80276)
![Anti-PD-L1 antibody [MIH6] - Low endotoxin, Azide free (ab80276)](https://www.abcam.com/ps/products/80/ab80276/Images/ab80276-366449-AntiPDL1-antibody-B7H1-Low-endotoxin-Azide-free-flow-cytometry-splenocytes-mouse.png "Anti-PD-L1 antibody [MIH6] - Low endotoxin, Azide free (ab80276)")
Key features and details
- Rat monoclonal [MIH6] to PD-L1 - Low endotoxin, Azide free
- Suitable for: Flow Cyt
- Reacts with: Mouse
- Isotype: IgG2a
Overview
-
Product name
Anti-PD-L1 antibody [MIH6] - Low endotoxin, Azide free
See all PD-L1 primary antibodies -
Description
Rat monoclonal [MIH6] to PD-L1 - Low endotoxin, Azide free -
Host species
Rat -
Tested Applications & Species
See all applications and species dataApplication Species Flow Cyt Mouse
-
Immunogen
Tissue, cells or virus corresponding to Mouse PD-L1. Mouse PD-L1-transfected cells.
-
Positive control
- Flow Cyt: C57BL/6 mouse splenocytes.
-
General notes
Please note the manufacture has changed and this item is currently only recommended for Flow Cytometry.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.20
Constituent: PBS -
Carrier free
Yes -
Concentration information loading... -
Purity
Affinity purified -
Purification notes
Clonality
MonoclonalClone number
MIH6Isotype
IgG2aLight chain type
kappaResearch areas
Associated products
-
Compatible Secondaries
-
Conjugation kits
-
Isotype control
-
Recombinant Protein
-
Related Products
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab80276 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
GuaranteedTested applications are guaranteed to work and covered by our Abpromise guarantee.
PredictedPredicted to work for this combination of applications and species but not guaranteed.
IncompatibleDoes not work for this combination of applications and species.
Application Species Flow Cyt MouseApplication Abreviews Notes Flow Cyt Use at an assay dependent concentration.Use ≤ 0.5 µg per million cells in 100 µl volume or 100 µl of whole blood.
Notes Flow Cyt
Use at an assay dependent concentration.Use ≤ 0.5 µg per million cells in 100 µl volume or 100 µl of whole blood.
Target
-
Function
Involved in the costimulatory signal, essential for T-cell proliferation and production of IL10 and IFNG, in an IL2-dependent and a PDCD1-independent manner. Interaction with PDCD1 inhibits T-cell proliferation and cytokine production. -
Tissue specificity
Highly expressed in the heart, skeletal muscle, placenta and lung. Weakly expressed in the thymus, spleen, kidney and liver. Expressed on activated T- and B-cells, dendritic cells, keratinocytes and monocytes. -
Sequence similarities
Belongs to the immunoglobulin superfamily. BTN/MOG family.
Contains 1 Ig-like C2-type (immunoglobulin-like) domain.
Contains 1 Ig-like V-type (immunoglobulin-like) domain. -
Cellular localization
Cell membrane and Endomembrane system. - Information by UniProt
-
Database links
- Entrez Gene: 60533 Mouse
- SwissProt: Q9EP73 Mouse
- Unigene: 245363 Mouse
-
Alternative names
- B7 H antibody
- B7 H1 antibody
- B7 homolog 1 antibody
see all
Images
-
Flow Cytometry - Anti-PD-L1 antibody [B7-H1] - Low endotoxin, Azide free (ab80276)
C57BL/6 mouse splenocytes were stained with ab80276 (purple filled histogram) or purified rat IgG2a, κ isotype control (black dashed line open histogram), followed by anti-Rat IgG PE.
Protocols
References (9)
ab80276 has been referenced in 9 publications.
- Sharma NS et al. Targeting tumor-intrinsic hexosamine biosynthesis sensitizes pancreatic cancer to anti-PD1 therapy. J Clin Invest 130:451-465 (2020). PubMed: 31613799
- Brenner E et al. Cancer immune control needs senescence induction by interferon-dependent cell cycle regulator pathways in tumours. Nat Commun 11:1335 (2020). PubMed: 32165639
- Yoo B et al. RNAi-Mediated PD-L1 Inhibition for Pancreatic Cancer Immunotherapy. Sci Rep 9:4712 (2019). PubMed: 30886310
- Zhao F et al. Stromal Fibroblasts Mediate Anti-PD-1 Resistance via MMP-9 and Dictate TGFß Inhibitor Sequencing in Melanoma. Cancer Immunol Res 6:1459-1471 (2018). PubMed: 30209062
- Zhang X et al. PD-1 Blockade Overcomes Adaptive Immune Resistance in Treatment with Anchored-GM-CSF Bladder Cancer Cells Vaccine. J Cancer 9:4374-4381 (2018). PubMed: 30519342
- Liu Y et al. Neuronal IFN-beta-induced PI3K/Akt-FoxA1 signalling is essential for generation of FoxA1(+)Treg cells. Nat Commun 8:14709 (2017). PubMed: 28436428
- Gray MJ et al. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers. Breast Cancer Res 18:50 (2016). PubMed: 27169467
- Guo Z et al. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer. J Transl Med 13:247 (2015). PubMed: 26219551
- Hirahara K et al. Interleukin-27 priming of T cells controls IL-17 production in trans via induction of the ligand PD-L1. Immunity 36:1017-30 (2012). PubMed: 22726954
Images
-
Flow Cytometry - Anti-PD-L1 antibody [B7-H1] - Low endotoxin, Azide free (ab80276)
C57BL/6 mouse splenocytes were stained with ab80276 (purple filled histogram) or purified rat IgG2a, κ isotype control (black dashed line open histogram), followed by anti-Rat IgG PE.
